Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 11 » Issue 1

The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis

Authors Miravitlles M, Chapman K, Chuecos F, Ribera A, Garcia Gil E

Received 8 June 2016

Accepted for publication 22 July 2016

Published 29 August 2016 Volume 2016:11(1) Pages 2041—2053

DOI https://doi.org/10.2147/COPD.S114566

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Amy Norman

Peer reviewer comments 3

Editor who approved publication: Dr Richard Russell

Marc Miravitlles,1 Kenneth R Chapman,2 Ferran Chuecos,3 Anna Ribera,4 Esther Garcia Gil3

1Department of Pneumology, Vall d’Hebron University Hospital, CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain; 2Asthma & Airway Centre, University Health Network, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada; 3Global Medicines Development, AstraZeneca PLC, Barcelona, Spain; 4Global Medical Affairs, AstraZeneca PLC, Barcelona, Spain

Background: Patients with chronic obstructive pulmonary disease (COPD) experience respiratory symptoms, which impair quality of life. This pooled analysis of two Phase III studies assessed the impact of aclidinium/formoterol on patients with COPD categorized by symptom status.
Methods: Data were pooled from two 24-week, randomized, placebo-controlled studies of twice-daily aclidinium/formoterol 400/12 µg in moderate-to-severe COPD (ACLIFORM [NCT01462942] and AUGMENT [NCT01437397]). These post hoc analyses evaluated the efficacy of aclidinium/formoterol versus placebo or monotherapies in patients defined as less/more symptomatic by a) Evaluating Respiratory Symptoms (E-RS™) score ≥10/<10 and b) Baseline Dyspnea Index score <7/≥7. Endpoints included trough and 1-hour morning postdose forced expiratory volume in 1 second (FEV1), Transition Dyspnea Index, E-RS total score, early-morning and nighttime symptom severity, early-morning limitation of activities, and exacerbation rate.
Results: Data for 3,394 patients were analyzed (mean age: 63.5 years; 60.5% male). In both definitions of less and more symptomatic patients, aclidinium/formoterol improved 1-hour morning postdose FEV1 from baseline at week 24 versus placebo (P<0.001) and both monotherapies (P<0.05). Aclidinium/formoterol improved trough FEV1 from baseline in both groups versus placebo (P<0.05) and formoterol (P<0.05); improvements were greater in more symptomatic patients. Improvements versus aclidinium were also observed in more symptomatic patients (P<0.05). Aclidinium/formoterol improved dyspnea, early-morning symptom severity, and limitation of activities versus placebo in both less and more symptomatic patients (P<0.001). In more symptomatic patients, aclidinium/formoterol also improved E-RS total score and severity of nighttime symptoms from baseline versus placebo and one or both monotherapies (P<0.05). The rate of moderate/severe exacerbations was reduced with aclidinium/formoterol versus placebo in more symptomatic patients.
Conclusion: Aclidinium/formoterol 400/12 µg provided consistent improvements in bronchodilation and symptoms versus monotherapies and reduced exacerbations versus placebo in more symptomatic patients with moderate-to-severe COPD, regardless of the definition used. Furthermore, patients with a low symptom burden achieved benefits with aclidinium/formoterol versus monotherapies in postdose FEV1, dyspnea, and early-morning symptoms.

Keywords: aclidinium, formoterol, COPD, lung function, dyspnea, symptoms

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Russian guidelines for the management of COPD: algorithm of pharmacologic treatment

Aisanov Z, Avdeev S, Arkhipov V, Belevskiy A, Chuchalin A, Leshchenko I, Ovcharenko S, Shmelev E, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:183-187

Published Date: 8 January 2018

Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique

Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, Soriano JB, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:57-67

Published Date: 21 December 2017

Gene and miRNA expression profiles in PBMCs from patients with severe and mild emphysema and PiZZ alpha1-antitrypsin deficiency

Esquinas C, Janciauskiene S, Gonzalo R, Mas de Xaxars G, Olejnicka B, Belmonte I, Barrecheguren M, Rodríguez E, Nuñez A, Rodríguez-Frías F, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:3381-3390

Published Date: 29 November 2017

Palliative care and prognosis in COPD: a systematic review with a validation cohort

Almagro P, Yun S, Sangil A, Rodríguez-Carballeira M, Marine M, Landete P, Soler-Cataluña JJ, Soriano JB, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1721-1729

Published Date: 9 June 2017

Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Lara B, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1683-1694

Published Date: 8 June 2017

Bronchiectasis in COPD patients: more than a comorbidity?

Martinez-Garcia MA, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1401-1411

Published Date: 11 May 2017

Self-reported daily walking time in COPD: relationship with relevant clinical and functional characteristics

Ramon MA, Esquinas C, Barrecheguren M, Pleguezuelos E, Molina J, Quintano JA, Roman-Rodríguez M, Naberan K, Llor C, Roncero C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:1173-1181

Published Date: 13 April 2017

Alpha-1 antitrypsin Pi*Z gene frequency and Pi*ZZ genotype numbers worldwide: an update

Blanco I, Bueno P, Diego I, Pérez-Holanda S, Casas-Maldonado F, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:561-569

Published Date: 13 February 2017

Diagnosis of alpha-1 antitrypsin deficiency: a population-based study

Barrecheguren M, Monteagudo M, Simonet P, Llor C, Rodriguez E, Ferrer J, Esquinas C, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:999-1004

Published Date: 10 May 2016

A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD

Miravitlles M, Montero-Caballero J, Richard F, Santos S, Garcia-Rivero JL, Ortega F, Ribera X

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:407-415

Published Date: 26 February 2016

Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients

Miravitlles M, Gáldiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F

International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:123-132

Published Date: 18 January 2016

The chronic obstructive pulmonary disease assessment test improves the predictive value of previous exacerbations for poor outcomes in COPD

Miravitlles M, García-Sidro P, Fernández-Nistal A, Buendía MJ, Espinosa de los Monteros MJ, Esquinas C, Molina J

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:2571-2579

Published Date: 30 November 2015

Is a previous diagnosis of asthma a reliable criterion for asthma–COPD overlap syndrome in a patient with COPD?

Barrecheguren M, Román-Rodríguez M, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1745-1752

Published Date: 1 September 2015

What pulmonologists think about the asthma–COPD overlap syndrome

Miravitlles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberri M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:1321-1330

Published Date: 15 July 2015

Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease

Miravitlles M, Huerta A, Valle M, García-Sidro P, Forné C, Crespo C, López-Campos JL

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:367-377

Published Date: 16 February 2015

Caregivers’ burden in patients with COPD

Miravitlles M, Peña-Longobardo LM, Oliva-Moreno J, Hidalgo-Vega Á

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:347-356

Published Date: 12 February 2015

The concept of control of COPD in clinical practice

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1397-1405

Published Date: 12 December 2014

Geographic differences in clinical characteristics and management of COPD: the EPOCA study

Marc Miravitlles, Cristina Murio, Gema Tirado-Conde, Gur Levy, Hana Muellerova, et al

International Journal of Chronic Obstructive Pulmonary Disease 2008, 3:803-814

Published Date: 5 December 2008